| Ytd | -61.32% | |
| 1y | -84.43% |
| Open | 1.09 | Prev Close | 1.11 | Low | 1.09 | High | 1.13 | Mkt Cap | 17.74M |
| Vol | 43.45K | Avg Vol | 196.40K | EPS | -5.70 | P/E | N/A | Forward P/E | -0.61 |
| Beta | -2.78 | Short Ratio | 0.39 | Inst. Own | 23.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.58 | 200-d Avg | 4.10 | 1yr Est | 18.75 |
TPST News
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000119312526257684/d91703d8k.htm
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.50) per share which missed the a
Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19
TPST-2003 is an autologous CD19/BCMA dual-targeting CAR-T therapy designed to improve response depth
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.62) per share which beat the ana
Tempest Therapeutics has entered into definitive agreements for the purchase and sale of an aggregat
Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, de
100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile w
HC Wainwright & Co. analyst Joseph Pantginis upgrades Tempest Therapeutics (NASDAQ:TPST) from
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of
Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dua
Matt Angel, Ph.D.Dr. Matt Angel is an experienced biotechnology executive with expertise in leading
Tempest will issue 8,268,495 shares of its common stock, par value $0.001 per share ("Common Sto
Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest" or "the Company"), a clinical-s
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.79) per share which beat the ana
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(2.07) per share which beat the ana
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast T
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(3.16) per share which beat the ana
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited
Correction: Scotiabank analyst George Farmer downgrades Tempest Therapeutics (NASDAQ:TPST) from Sect
HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics (NASDAQ:TPST) fr
Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal st
Scotiabank analyst George Farmer maintains Tempest Therapeutics (NASDAQ:TPST) with a Sector Outpe
HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) wit
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(1.50) per share which missed the a
Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in
Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in
Piper Sandler analyst Edward Tenthoff maintains Tempest Therapeutics (NASDAQ:TPST) with a Overwei
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) wi
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the comp
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after repor